Lennart B van Rijssen1, Poorvi Narwade1, Nadine C M van Huijgevoort1, Dorine S J Tseng2, Hjalmar C van Santvoort3, Isaac Q Molenaar2, Hanneke W M van Laarhoven4, Casper H J van Eijck5, Olivier R C Busch1, Marc G H Besselink6. 1. Department of Surgery, Academic Medical Center, Amsterdam, Netherlands. 2. Department of Surgery, Utrecht Medical Center, Utrecht, Netherlands. 3. Department of Surgery, Academic Medical Center, Amsterdam, Netherlands; Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands. 4. Department of Medical Oncology, Academic Medical Center, Amsterdam, Netherlands. 5. Department of Surgery, Erasmus Medical Center, Rotterdam, Netherlands. 6. Department of Surgery, Academic Medical Center, Amsterdam, Netherlands. Electronic address: m.g.besselink@amc.nl.
Abstract
BACKGROUND: Hepatic-artery and para-aortic lymph node metastases (LNM) may be detected during surgical exploration for pancreatic (PDAC) or periampullary cancer. Some surgeons will continue the resection while others abort the exploration. METHODS: A systematic search was performed in PubMed, EMBASE and Cochrane Library for studies investigating survival in patients with intra-operatively detected hepatic-artery or para-aortic LNM. Survival was stratified for node positive (N1) disease. RESULTS: After screening 3088 studies, 13 studies with 2045 patients undergoing pancreatoduodenectomy were included. No study reported survival data after detection of LNM and aborted surgical exploration. In 110 patients with hepatic-artery LNM, median survival ranged between 7 and 17 months. Estimated pooled mean survival in 84 patients with hepatic-artery LNM was 15 [95%CI 12-18] months (13 months in PDAC), compared to 19 [16-22] months in 270 patients with N1-disease without hepatic-artery LNM (p = 0.020). In 192 patients with para-aortic LNM, median survival ranged between 5 and 32 months. Estimated pooled mean survival in 169 patients with para-aortic LNM was 13 [8-17] months (11 months in PDAC), compared to 17 (6-27) months in 506 patients with N1-disease without para-aortic LNM (p < 0.001). Data on the impact of (neo)adjuvant therapy on survival were lacking. CONCLUSION: Survival after pancreatoduodenectomy in patients with intra-operatively detected hepatic-artery and especially para-aortic LNM is inferior to patients undergoing pancreatoduodenectomy with other N1 disease. It remains unclear what the consequence of this should be since data on (neo-)adjuvant therapy and survival after aborted exploration are lacking.
BACKGROUND: Hepatic-artery and para-aortic lymph node metastases (LNM) may be detected during surgical exploration for pancreatic (PDAC) or periampullary cancer. Some surgeons will continue the resection while others abort the exploration. METHODS: A systematic search was performed in PubMed, EMBASE and Cochrane Library for studies investigating survival in patients with intra-operatively detected hepatic-artery or para-aortic LNM. Survival was stratified for node positive (N1) disease. RESULTS: After screening 3088 studies, 13 studies with 2045 patients undergoing pancreatoduodenectomy were included. No study reported survival data after detection of LNM and aborted surgical exploration. In 110 patients with hepatic-artery LNM, median survival ranged between 7 and 17 months. Estimated pooled mean survival in 84 patients with hepatic-artery LNM was 15 [95%CI 12-18] months (13 months in PDAC), compared to 19 [16-22] months in 270 patients with N1-disease without hepatic-artery LNM (p = 0.020). In 192 patients with para-aortic LNM, median survival ranged between 5 and 32 months. Estimated pooled mean survival in 169 patients with para-aortic LNM was 13 [8-17] months (11 months in PDAC), compared to 17 (6-27) months in 506 patients with N1-disease without para-aortic LNM (p < 0.001). Data on the impact of (neo)adjuvant therapy on survival were lacking. CONCLUSION: Survival after pancreatoduodenectomy in patients with intra-operatively detected hepatic-artery and especially para-aortic LNM is inferior to patients undergoing pancreatoduodenectomy with other N1 disease. It remains unclear what the consequence of this should be since data on (neo-)adjuvant therapy and survival after aborted exploration are lacking.
Authors: Alessandro Paniccia; Patrick Hosokawa; William Henderson; Richard D Schulick; Barish H Edil; Martin D McCarter; Csaba Gajdos Journal: JAMA Surg Date: 2015-08 Impact factor: 14.766
Authors: J A M G Tol; L A A Brosens; S van Dieren; T M van Gulik; O R C Busch; M G H Besselink; D J Gouma Journal: Br J Surg Date: 2014-12-22 Impact factor: 6.939
Authors: Giuseppe Malleo; Laura Maggino; Paola Capelli; Francesco Gulino; Silvia Segattini; Aldo Scarpa; Claudio Bassi; Giovanni Butturini; Roberto Salvia Journal: J Am Coll Surg Date: 2015-02-28 Impact factor: 6.113
Authors: S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi Journal: Ann Surg Date: 1998-10 Impact factor: 12.969
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban Journal: Ann Surg Date: 2002-09 Impact factor: 12.969
Authors: John DeWitt; Benedict Devereaux; Melissa Chriswell; Kathleen McGreevy; Thomas Howard; Thomas F Imperiale; Donato Ciaccia; Kathleen A Lane; Dean Maglinte; Kenyon Kopecky; Julia LeBlanc; Lee McHenry; James Madura; Alex Aisen; Harvey Cramer; Oscar Cummings; Stuart Sherman Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Sebastian Hempel; Florian Oehme; Benjamin Müssle; Daniela E Aust; Marius Distler; Hans-Detlev Saeger; Jürgen Weitz; Thilo Welsch Journal: World J Surg Oncol Date: 2020-01-21 Impact factor: 2.754